Lentigo maligna melanoma (LMM) represents a subtype of cutaneous melanoma developing on extensively sun-damaged skin, typically in elderly individuals. The lesion develops from lentigo maligna, an in situ melanoma (melanoma confined to epidermis), through malignant progression into dermis. This melanoma subtype accounts for 5% to 15% of all cutaneous melanomas and carries intermediate prognosis between favorable superficial spreading melanoma and aggressive nodular melanoma. Early detection of lentigo maligna before dermal invasion substantially improves outcomes, with five-year survival exceeding 90% for melanoma in situ versus 70% to 80% for invasive LMM.

Lentigo Maligna: In Situ Precursor to Invasive Melanoma

Lentigo maligna presents as slowly enlarging, irregularly-shaped macule with variable brown, tan, and black coloration. Lesions typically measure 1 to 3 centimeters at diagnosis but may expand to 5 to 10 centimeters or larger. Distinctive features include asymmetry, irregular border, and multicolored appearance. Lesions develop on sun-exposed areas including face, ears, and neck, typically in elderly individuals with significant cumulative solar exposure. The slow growth over years to decades contrasts with rapid development of other melanoma subtypes.

Histopathologically, lentigo maligna demonstrates lentiginous (orderly single-cell) infiltration of atypical melanocytes along basal-epidermal junction with extension into follicles and surrounding sun-damaged tissue. The orderly growth pattern and predominant junctional component distinguish lentigo maligna from superficial spreading melanoma. Solar elastosis (solar-induced dermal changes) provides evidence of photodamage background.

Malignant transformation of lentigo maligna to invasive melanoma occurs over years to decades. Transformation rates approximate 5% to 10% over 10 years, though this varies substantially with individual factors. The development of thickening, induration, or nodular component within previously flat lentigo maligna indicates invasive progression warranting immediate evaluation.

Lentigo Maligna Melanoma: Invasive Presentation and Breslow Thickness

When dermal invasion occurs, lentigo maligna melanoma develops with combination of superficial lentiginous junctional component and dermal melanocytic nests. Breslow thickness measurement critically determines prognosis. LMM demonstrates variable thickness ranging from minimal (0.5 to 1.0 millimeter) to extensive (greater than 4.0 millimeters). Mean Breslow thickness for LMM approximates 1.5 to 2.0 millimeters, intermediate between superficial spreading melanoma (mean 1.0 to 1.5 millimeters) and nodular melanoma (mean 3.0+ millimeters).

Five-year survival for thin LMM (Breslow thickness less than 1.0 millimeter) exceeds 95%. Lesions 1.0 to 2.0 millimeters thick show five-year survival of 85% to 90%. Thicker lesions (greater than 4.0 millimeters) demonstrate five-year survival declining to 50% to 60%. Ulceration, when present, substantially worsens prognosis; ulcerated LMM shows 1.4 to 2.0-fold increased mortality risk compared to non-ulcerated lesions of equivalent thickness.

Diagnostic Challenges and Dermoscopic Features

Lentigo maligna diagnosis remains challenging, particularly in early stages when the lesion may resemble benign solar lentigo. Dermoscopic examination reveals characteristic patterns including reticulated (lattice-like) pigment network, follicular pigmentation, and asymmetric follicular openings. Solar lentigos show more uniform patterns without the asymmetric irregular features characteristic of lentigo maligna. However, overlap exists; clinical correlation remains essential.

Biopsy confirmation proves essential for diagnosis. The challenge of completely sampling lesions that may extend over large areas necessitates multiple punch biopsies from lesion periphery where diagnostic features often concentrate. Some lesions require multiple sequential biopsies over time to establish diagnosis.

Surgical Treatment and Mohs Micrographic Surgery

Standard Wide Excision: Surgical excision with margins represents standard treatment for lentigo maligna and lentigo maligna melanoma. Recommended margins typically approximate 5 to 10 millimeters for lentigo maligna (in situ disease) and 1 to 2 centimeters for invasive LMM depending on Breslow thickness. Complete histopathological examination confirms removal and measures Breslow thickness in invasive disease.

Mohs Micrographic Surgery: Mohs surgery provides superior outcomes for lentigo maligna, particularly on face where cosmetic preservation matters. Mohs surgery applied to lentigo maligna achieves complete removal while preserving normal tissue. Recurrence rates with Mohs surgery approximate 2% to 5%, substantially lower than standard excision (10% to 15%). Specialized Mohs technique using melanoma-specific immunohistochemical staining (S100, SOX10, Melan-A) enhances visualization of melanocytic atypia during intraoperative assessment.

Reconstruction: Post-excision defects require reconstruction with consideration for functional and cosmetic outcomes. Small defects heal by secondary intention or simple closure. Larger facial defects often benefit from local flaps or grafts. Reconstruction planning should prioritize adequate margin achievement; adequate removal supersedes cosmetic simplicity.

Non-Surgical Treatment Options

Topical Chemotherapy: Topical 5-fluorouracil (5%) and imiquimod (5%) have been investigated for lentigo maligna treatment. 5-FU applied twice daily for 4 to 12 weeks demonstrates response rates of 60% to 80% in small uncontrolled series. Imiquimod applied 3 to 5 times weekly for 8 to 16 weeks achieves similar response rates. However, long-term recurrence data remain limited; topical therapy may be considered for poor surgical candidates or combination approach following surgical debulking.

Radiation Therapy: Radiation therapy provides alternative for patients unable or unwilling to undergo surgery. External beam radiotherapy delivers 50 to 60 gray total dose in conventional fractionation. Local control rates approximate 85% to 95% with cosmetically acceptable outcomes in most patients. Radiation represents reasonable option for elderly patients with significant medical comorbidities precluding anesthesia.

Cryotherapy: Cryotherapy using liquid nitrogen achieves variable results in lentigo maligna. Cure rates prove lower than excision (70% to 80% versus 95%+) and recurrence risk remains elevated. Cryotherapy lacks ability to assess histology, potentially missing invasive melanoma. Cryotherapy use in lentigo maligna management remains limited.

Surveillance and Long-Term Management

Patients treated for lentigo maligna or lentigo maligna melanoma require systematic surveillance for recurrent disease at treatment site and development of additional skin cancers. Clinical examination every 3 to 6 months for first 2 to 3 years, then annual evaluation, identifies recurrent disease early. Photographic documentation of treatment site and surrounding skin enables comparison during follow-up visits.

Strict sun protection proves essential given extensive underlying photodamage predisposing these patients to additional malignancies. Broad-spectrum sunscreen (SPF 30+), protective clothing, and limiting peak sun exposure reduce risk of new skin cancers. Aggressive photoprotection introduced at this stage, while unable to reverse prior damage, slows development of additional lesions.

FAQ

Is lentigo maligna definitely cancer?

Lentigo maligna represents melanoma in situ (nonmelanoma confined to epidermis without dermal invasion). The malignant status indicates that without treatment, approximately 5% to 10% transform to invasive melanoma within 10 years. However, many lentigo malignas remain stable indefinitely. Treatment remains recommended to eliminate transformation risk.

What is the difference between lentigo maligna and lentigo maligna melanoma?

Lentigo maligna represents in situ melanoma confined to epidermis. Lentigo maligna melanoma develops when dermal invasion occurs, creating invasive disease. The distinction carries substantial prognostic importance: five-year survival exceeds 95% for lentigo maligna but is 70% to 80% for invasive LMM.

Is Mohs surgery better than regular excision for lentigo maligna?

Mohs surgery shows superior outcomes with recurrence rates of 2% to 5% compared to 10% to 15% for standard excision. Mohs surgery provides enhanced visualization of melanocytic atypia while maximizing normal tissue preservation. Mohs surgery represents preferred approach particularly for facial lentigo maligna. Standard excision remains acceptable for peripheral body locations where cosmetics matter less.

Do I need a sentinel lymph node biopsy for lentigo maligna melanoma?

Sentinel lymph node biopsy proves most valuable for melanomas with Breslow thickness greater than 1.0 to 1.2 millimeters. Many lentigo maligna melanomas remain thin with minimal lymph node risk; SLNB provides most value in thicker invasive lesions. Individual assessment of thickness and other risk factors guides SLNB recommendations.

References

1. Sober AJ, Fitzpatrick TB, Mihm MC Jr. Early recognition of cutaneous melanoma. Journal of the American Academy of Dermatology. 1979;1(2):143-150. Clinical features and early detection discussion.

2. Haberland H, Jung EG. Lentigo maligna and lentigo maligna melanoma. Dermatology. 1990;181(3):222-230. Pathological characterization and natural history.

3. Goldberg DJ, Amin S, Hussain M. Mohs micrographic surgery of skin cancer. Journal of Dermatological Treatment. 2002;13(2):63-75. Mohs technique for melanocytic lesions.

4. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer Journal for Clinicians. 2004;54(3):131-149. TNM staging incorporating Breslow thickness.

5. Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Journal of Clinical Oncology. 2012;30(23):2912-2918. SLNB indication recommendations.

6. Jemal A, Saraiya M, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2004. Cancer. 2007;110(9):2119-2152. Population-based epidemiological data.

7. Atallah E, Flaherty L. Update on cutaneous melanoma. Current Opinion in Oncology. 2005;17(2):155-169. Clinical presentation and management overview.

8. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncology. 2002;3(3):159-165. Dermoscopic pattern assessment.

9. Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma. Journal of the National Comprehensive Cancer Network. 2019;17(4):367-402. Contemporary treatment guidelines.

10. Hazan C, Abbasi NR, Khatri K, et al. Mohs micrographic surgery for lentigo maligna: a systematic review. Archives of Dermatology. 2007;143(6):732-739. Comparative outcomes with standard excision.